Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

As the Affordable Care Act passed its 15th anniversary this year, Supreme Court Justices continue to deliberate the fate of ...

John Michael O'Brien, PharmD, MPH, discussed the changes in managed care over the past 30 years to commemorate the 30th ...

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't ...

Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic ...

Panelists discuss how sulopenem etzadroxil/probenecid, approved in October 2024, functions as an oral β-lactam/β-lactamase inhibitor effective against extended-spectrum β-lactamase producers per SURE ...

Panelists discuss how developing effective management protocols for amyloid-related imaging abnormalities (ARIA) requires implementing robust baseline and follow-up MRI monitoring schedules, ...

Panelists discuss how newer urinary tract infection (UTI) therapies such as pivmecillinam, sulopenem etzadroxil/probenecid, and gepotidacin demonstrate significantly lower resistance rates (below 5%) ...

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.